-
Two clinical trials of adult male circumcision have been halted after an interim review of data showed medically performed circumcision significantly lowers a man's risk of acquiring HIV through heterosexual intercourse.
-
Research regarding the safety and efficacy of the first continuous regimen oral contraceptive (OC) has just been published, with results indicating a good safety profile and efficacy similar to cyclic OCs.
-
Results of a new analysis of national data indicate that 86% of the recent drop in U.S. teen pregnancy rates is the result of improved contraceptive use, while 14% of the decline can be attributed to teens waiting longer to start having sex.
-
Acceptance of the first human papillomavirus (HPV) vaccine continues to grow, as the national immunization schedule for children and teens has been updated to include Gardasil, manufactured by Merck & Co., of Whitehouse Station, NJ.
-
Using hormonal contraception does not appear to increase women's overall risk of infection with the AIDS virus, according to results from a new study commissioned by the National Institute of Child Health and Human Development (NICHD).
-
Choosing depot medroxyprogesterone acetate (DMPA, Depo Provera, Pfizer, New York City) may free women from taking a daily pill, but they must return to providers' offices for quarterly injections. What if pharmacists could administer repeat injections?
-
Nurse practitioners, physician assistants, and certified nurse-midwives provide many health services in family planning, yet many of their training programs do not provide didactic or clinical education about abortion services, results from a recently published survey show.
-
Results from a recently published study suggest that combination oral contraceptives (OCs) and oral medroxyprogesterone acetate (MPA) may be effective treatment options for acute uterine bleeding.
-
Rewind to 1997: President Clinton announces a 10-year goal for the development of an HIV/ AIDS vaccine. Fast forward to 2007. Are you able to provide such a vaccine to your patients?
-
What if you could offer your patients emergency contraception (EC) in a single tablet with one-time dosing? Scientists are looking at CDB-2914, a new progesterone receptor modulator (PRM), that may provide EC in such a dosing regimen.